Nanofiltration as a robust method contributing to viral safety of plasma‐derived therapeutics: 20 yearsʼ experience of the plasma protein manufacturers
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nanofiltration as a robust method contributing to viral safety of plasma‐derived therapeutics: 20 yearsʼ experience of the plasma protein manufacturers
Authors
Keywords
-
Journal
TRANSFUSION
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-08-28
DOI
10.1111/trf.16022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Role of Nanofiltration in the Pathogen Safety of Biologicals: An Update
- (2019) Masaharu Inouye et al. Current Nanoscience
- Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa
- (2017) Tracey W. Ellgaard et al. PROTEIN EXPRESSION AND PURIFICATION
- Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration
- (2017) Thomas Nowak et al. TRANSFUSION
- Effective inactivation of a wide range of viruses by pasteurization
- (2017) Albrecht Gröner et al. TRANSFUSION
- Inactivation and removal of Zika virus during manufacture of plasma-derived medicinal products
- (2016) Johannes Blümel et al. TRANSFUSION
- Single-use technology for solvent/detergent virus inactivation of industrial plasma products
- (2016) Yao-Ting Hsieh et al. TRANSFUSION
- Characterization of Thrombate III®, a pasteurized and nanofiltered therapeutic human antithrombin concentrate
- (2014) Kang Cai et al. BIOLOGICALS
- Pathogen safety of Beriate®
- (2014) Albrecht Gröner THROMBOSIS RESEARCH
- Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step
- (2012) A.H.L. Koenderman et al. BIOLOGICALS
- Pathogen safety of human C1 esterase inhibitor concentrate
- (2012) Albrecht Gröner et al. TRANSFUSION
- Viral safety characteristics of Flebogamma® DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin
- (2010) Santiago Caballero et al. BIOLOGICALS
- Evaluation of the Virus-elimination Efficacy of Nanofiltration (Viresolve NFP) for the Parvovirus B19 and Hepatitis A Virus
- (2010) Deok Ja Oh et al. Korean Journal of Laboratory Medicine
- Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies
- (2009) Herbert O. Dichtelmüller et al. TRANSFUSION
- Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products
- (2009) M. C. Menconi et al. TRANSFUSION MEDICINE
- Investigations of prion and virus safety of a new liquid IVIG product
- (2008) M. Stucki et al. BIOLOGICALS
- A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity
- (2008) G. Poelsler et al. VOX SANGUINIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started